Correlation Between Telix Pharmaceuticals and Burzynski Research
Can any of the company-specific risk be diversified away by investing in both Telix Pharmaceuticals and Burzynski Research at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Telix Pharmaceuticals and Burzynski Research into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Telix Pharmaceuticals Limited and Burzynski Research, you can compare the effects of market volatilities on Telix Pharmaceuticals and Burzynski Research and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Telix Pharmaceuticals with a short position of Burzynski Research. Check out your portfolio center. Please also check ongoing floating volatility patterns of Telix Pharmaceuticals and Burzynski Research.
Diversification Opportunities for Telix Pharmaceuticals and Burzynski Research
-0.06 | Correlation Coefficient |
Good diversification
The 3 months correlation between Telix and Burzynski is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Telix Pharmaceuticals Limited and Burzynski Research in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Burzynski Research and Telix Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Telix Pharmaceuticals Limited are associated (or correlated) with Burzynski Research. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Burzynski Research has no effect on the direction of Telix Pharmaceuticals i.e., Telix Pharmaceuticals and Burzynski Research go up and down completely randomly.
Pair Corralation between Telix Pharmaceuticals and Burzynski Research
Assuming the 90 days horizon Telix Pharmaceuticals Limited is expected to generate 0.23 times more return on investment than Burzynski Research. However, Telix Pharmaceuticals Limited is 4.33 times less risky than Burzynski Research. It trades about 0.24 of its potential returns per unit of risk. Burzynski Research is currently generating about 0.05 per unit of risk. If you would invest 1,340 in Telix Pharmaceuticals Limited on September 2, 2024 and sell it today you would earn a total of 210.00 from holding Telix Pharmaceuticals Limited or generate 15.67% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Telix Pharmaceuticals Limited vs. Burzynski Research
Performance |
| Timeline |
| Telix Pharmaceuticals |
| Burzynski Research |
Telix Pharmaceuticals and Burzynski Research Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Telix Pharmaceuticals and Burzynski Research
The main advantage of trading using opposite Telix Pharmaceuticals and Burzynski Research positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Telix Pharmaceuticals position performs unexpectedly, Burzynski Research can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Burzynski Research will offset losses from the drop in Burzynski Research's long position.| Telix Pharmaceuticals vs. Rigel Pharmaceuticals | Telix Pharmaceuticals vs. Geron | Telix Pharmaceuticals vs. Verastem | Telix Pharmaceuticals vs. Immutep Ltd ADR |
| Burzynski Research vs. ProKidney Corp | Burzynski Research vs. Orchestra BioMed Holdings | Burzynski Research vs. Lixte Biotechnology Holdings | Burzynski Research vs. Oncology Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |